Original Article
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Translational Lung Cancer Research
2022;
11
(6)
:953-963
.
(30 June 2022)
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
Translational Lung Cancer Research
2022;
11
(6)
:964-974
.
(30 June 2022)
Correlation of tumor microenvironment-related markers with clinical outcomes in patients with squamous cell carcinoma of the lung
Translational Lung Cancer Research
2022;
11
(6)
:975-990
.
(30 June 2022)
Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
Translational Lung Cancer Research
2022;
11
(6)
:991-1008
.
(30 June 2022)
Predictive performance of selected breath volatile organic carbon compounds in stage 1 lung cancer
Translational Lung Cancer Research
2022;
11
(6)
:1009-1018
.
(30 June 2022)
Feasibility and safety of pedicled autologous bronchial flap reconstruction airway instead of sleeve lobectomy in partial lung cancer surgery
Translational Lung Cancer Research
2022;
11
(6)
:1019-1026
.
(30 June 2022)
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study
Translational Lung Cancer Research
2022;
11
(6)
:1027-1037
.
(30 June 2022)
Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study
Translational Lung Cancer Research
2022;
11
(6)
:1038-1050
.
(30 June 2022)
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
Translational Lung Cancer Research
2022;
11
(6)
:1051-1068
.
(30 June 2022)
Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial
Translational Lung Cancer Research
2022;
11
(6)
:1069-1078
.
(30 June 2022)
Re-evaluating the need for mediastinal lymph node dissection and exploring lncRNAs as biomarkers of N2 metastasis in T1 lung adenocarcinoma
Translational Lung Cancer Research
2022;
11
(6)
:1079-1088
.
(30 June 2022)
Targeting STT3A produces an anti-tumor effect in lung adenocarcinoma by blocking the MAPK and PI3K/AKT signaling pathway
Translational Lung Cancer Research
2022;
11
(6)
:1089-1107
.
(30 June 2022)
Comparison of the perioperative outcomes between robotic-assisted thoracic surgery and video-assisted thoracic surgery in non-small cell lung cancer patients with different body mass index ranges
Translational Lung Cancer Research
2022;
11
(6)
:1108-1118
.
(30 June 2022)
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study
Translational Lung Cancer Research
2022;
11
(6)
:1119-1131
.
(30 June 2022)
A random forest algorithm predicting model combining intraoperative frozen section analysis and clinical features guides surgical strategy for peripheral solitary pulmonary nodules
Translational Lung Cancer Research
2022;
11
(6)
:1132-1144
.
(30 June 2022)
Intraoperative methods for wrapping anastomoses after airway reconstruction: a case series
Translational Lung Cancer Research
2022;
11
(6)
:1145-1153
.
(30 June 2022)
The procedure and effectiveness of release maneuvers in tracheobronchial resection and reconstruction
Translational Lung Cancer Research
2022;
11
(6)
:1154-1164
.
(30 June 2022)
Partitioning the lung field based on the depth ratio in three-dimensional space
Translational Lung Cancer Research
2022;
11
(6)
:1165-1175
.
(30 June 2022)
iMDT Corner
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
Translational Lung Cancer Research
2022;
11
(6)
:1176-1184
.
(30 June 2022)
Review Article
Comparative characteristics of small cell lung cancer and Ewing’s sarcoma: a narrative review
Translational Lung Cancer Research
2022;
11
(6)
:1185-1198
.
(30 June 2022)
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
Translational Lung Cancer Research
2022;
11
(6)
:1199-1216
.
(30 June 2022)
A narrative review of deep learning applications in lung cancer research: from screening to prognostication
Translational Lung Cancer Research
2022;
11
(6)
:1217-1229
.
(30 June 2022)
